3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Breast Neoplasms
17
Prostatic Neoplasms
6
Ovarian Neoplasms
6
Neoplasms
5
Triple Negative Breast Neoplasms
4
Neoplasm Metastasis
4
Stomach Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Solid Tumors
2
Multiple Myeloma
2
Mouth Neoplasms
2
Lymphoma
2
Laryngeal Neoplasms
2
Hypopharyngeal Neoplasms
2
Glioblastoma
2
Fallopian Tube Neoplasms
2
Carcinoma
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Cancers
1
Skin Diseases
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Interventions
Carboplatin
12
Paclitaxel
11
Gemcitabine
11
Capecitabine
7
Irinotecan
6
Fluorouracil
5
Cisplatin
5
Radiotherapy
4
Oxaliplatin
4
Leucovorin
4
Bevacizumab
4
pembrolizumab
3
Filgrastim
3
Etoposide
3
Erlotinib Hydrochloride
3
Cyclophosphamide
3
etoposide phosphate
2
atezolizumab
2
Trastuzumab
2
Topotecan
2
Taxes
2
Surveys and Questionnaires
2
Peripheral Blood Stem Cell Transplantation
2
Magnetic Resonance Spectroscopy
2
Genetic Testing
2
FAPI-46
2
Docetaxel
2
CP protocol
2
Amifostine
2
Albumin-Bound Paclitaxel
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms, Unknown Primary
×
ipatasertib
×
Clear all
NCT03498521
2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2
Completed
529 enrolled
16 charts